Association of the HIF-1α 1790 G/A polymorphism with cancer risk The results on all 12 studies showed no evidence that the HIF-1α 1790 G/A polymorphism was significantly associated with an increased cancer risk (P > 0.05) (Table 2, Figure 4). selleckchem The significant association between the A allele and the increased cancer risk was detected in other cancers: OR = 2.31 [95% CI (1.12, 4.75)], P = 0.02, Pheterogeneity = 0.0004 (Table IV) (Table

2). A marginal association between the 1790 G/A polymorphism and the increased cancer risk in other cancers was also detected under dominant model: OR = 2.22 [95% CI (0.95, 5.20)], P = 0.06, Pheterogeneity < 0.00001 (Table 2). The AZD1390 order pooled ORs for allelic frequency comparison and dominant model comparison suggested the 1790 G/A polymorphism was significantly associated with an increased cancer risk in Caucasians: OR = 3.08 [95% CI (1.49, 6.36)],

P = 0.002, Pheterogeneity = 0.04, and OR = 2.60 [95% CI (1.03, 6.59)], P = 0.04, Pheterogeneity = 0.002, respectively (Table 2). However, reanalysis after exclusion the studies with controls not in HWE did not suggest these associations (P > 0.05) (Table 2). The pooled ORs for A versus G and (AA+AG) versus GG suggested that 1790 G/A polymorphism was significantly associated with a decreased breast cancer risk: OR = 0.28 [95% CI (0.08, 0.90)], P = 0.03, Pheterogeneity = 0.45, and OR = 0.29 [95% CI (0.09, Integrin inhibitor 0.97)], P = 0.04, Pheterogeneity = 0.41, respectively (Table 2, Figure 4). The remaining pooled ORs on the association of 1790 G/A polymorphism and cancer risk were not significant (P > 0.05) (Table 2). Table 2 Meta-analysis of the HIF-1α 1790 G/A polymorphism and cancer association. Genetic contrasts Group and subgroups under analysis Studies (n) Q test P value Model seclected OR (95% CI) P A versus G Overall 12 <0.00001 Random 1.61 (0.75, 3.45) 0.22   Overall in HWE 11 0.0002 Random 1.32 (0.54, 3.24) 0.54   Caucasian 9 0.04 Random 3.08 (1.49, 6.36) 0.002   Caucasian in HWE 8 0.02 Random 2.15 (0.66, 7.02) 0.20   Dapagliflozin East Asian 2 0.33 Fixed 0.58 (0.24, 1.40) 0.23   Female* 5 0.07 Random 0.65 (0.07, 6.05) 0.71   Male

(prostate cancer)** 2 0.64 Fixed 0.96 (0.49, 1.90) 0.91   Breast cancer 2 0.45 Fixed 0.28 (0.08,0.90) 0.03   Other cancers 10 0.0004 Random 2.31 (1.12, 4.75) 0.02   Other cancers in HWE 9 0.002 Random 1.97 (0.79, 4.90) 0.15 (AA+AG) versus GG Overall 12 <0.00001 Random 1.56 (0.66, 3.65) 0.31   Overall in HWE 11 0.0004 Random 1.25 (0.53, 2.97) 0.61   Caucasian 9 0.002 Random 2.60 (1.03, 6.59) 0.04   Caucasian in HWE 8 0.004 Random 1.80 (0.50, 6.54) 0.37   East Asian 2 0.41 Fixed 0.61 (0.25, 1.51) 0.29   Female* 5 0.08 Random 0.68 (0.07, 6.30) 0.74   Male (prostate cancer) ** 2 0.64 Fixed 0.96 (0.49, 1.90) 0.91   Breast cancer 2 0.41 Fixed 0.29 (0.09, 0.97) 0.04   Other cancers 10 <0.00001 Random 2.22 (0.95, 5.20) 0.06   Other cancers in HWE 9 0.002 Random 1.